For the Quarter Ending September 2025
North America
• In the United States, the Apixaban Price Index rose in Q3 2025, reflecting strengthening production costs and robust healthcare spending.
• Apixaban production costs increased in Q3 2025, driven by a 2.6% PPI rise in August 2025 and strengthened chemical input costs.
• Demand for Apixaban was supported by strengthening US pharmaceutical market sentiment and accelerating national healthcare spending.
• Industrial electricity costs strengthened in September 2025, contributing to higher Apixaban manufacturing expenses.
• US chemical production contracted in Q3 2025, reflecting weak 0.1% industrial production growth in September 2025.
• US chemical manufacturing inventories tightened in Q3 2025 due to accelerating destocking, impacting Apixaban supply.
• Retail sales increased 5.42% in September 2025, indicating strong consumer spending, contrasting with declining consumer confidence (94.2).
• The unemployment rate was 4.3% in September 2025, posing potential barriers to healthcare access and Apixaban affordability.
Why did the price of Apixaban change in September 2025 in North America?
• Production costs increased due to a 3.0% CPI rise in September 2025 and strengthened general chemical input costs.
• Strong US pharmaceutical market sentiment and accelerating national healthcare spending boosted Apixaban demand.
• Tightening chemical manufacturing inventories and weakened pharmaceutical exports influenced Apixaban supply.
Europe
• In Germany, the Apixaban Price Index fell quarter-over-quarter in Q3 2025, influenced by declining producer prices for the pharmaceutical industry.
• Apixaban production costs declined in Q3 2025, supported by a -1.7% year-over-year decrease in producer prices in September 2025.
• Easing naphtha feedstock prices and declining European natural gas prices in Q3 2025 contributed to lower Apixaban production expenses.
• Apixaban demand remained steady in Q3 2025, supported by firming pharmaceutical output and a 3.9% unemployment rate in September 2025.
• Moderate inflation, with CPI at 2.4% year-over-year in September 2025, increased operational costs for Apixaban manufacturers.
• Weakening consumer confidence (-23.6 in September 2025) indirectly influenced healthcare spending, despite modest retail sales growth.
• Chemical industry inventories tightened in Q3 2025 due to accelerated destocking activities, impacting supply dynamics.
• The manufacturing index was contracting in September 2025, reflecting a -1.0% year-over-year decline in industrial production.
Why did the price of Apixaban change in September 2025 in Europe?
• Producer prices for the chemical and pharmaceutical industry declined in Q3 2025, reducing input costs for Apixaban.
• Naphtha feedstock prices eased in Q3 2025, alongside declining European natural gas prices, lowering energy expenses.
• Overall chemical demand weakened in Q3 2025, contributing to downward price pressure despite firming pharmaceutical output.
APAC
• In China, the Apixaban Price Index fell quarter-over-quarter in Q3 2025, influenced by deflationary pressures and market oversupply conditions.
• Apixaban production costs declined in September 2025, as producer prices for raw chemical materials decreased year-on-year by -2.3%.
• Persistent global oversupply and increased domestic capacity in Q3 2025 exerted significant downward pressure on the Apixaban Price Index.
• Demand for Apixaban intermediates showed strong growth in Q3 2025, supported by rising pharmaceutical R&D activities in China.
• Weakened industrial electricity prices in some major Chinese hubs in Q3 2025 contributed to lower Apixaban manufacturing expenses.
• China's Manufacturing Index was contracting in September 2025, indirectly impacting overall economic sentiment for the chemical sector.
• The Apixaban Price Forecast suggests continued moderation, given the -0.3% year-on-year CPI in September 2025.
• Apixaban demand outlook remained stable in Q3 2025, supported by a 5.2% unemployment rate in September 2025.
Why did the price of Apixaban change in September 2025 in APAC?
• Producer prices for raw chemical materials declined by -2.3% year-on-year in September 2025, reducing Apixaban production costs.
• China's chemical industry experienced oversupply and increased capacity in Q3 2025, exerting downward pressure on prices.
• Deflationary pressures, with CPI at -0.3% year-on-year in September 2025, contributed to a falling Apixaban Price Index.
For the Quarter Ending December 2022
North America
The Apixaban API market in North America displayed an erratic pattern in the fourth quarter of 2022. Prices were anticipated to increase in the second month of Q4 2022 as a result of rising end-user sector demand and other logistical difficulties. Zero covid rules were implemented, causing trade to be hampered and halted shipments, further influencing the market.
Despite greater production costs driven by rising energy prices, the market remained competitive. However, later in December, due to domestic retailers having an adequate supply on hand, Apixaban API prices decreased. By the end of Q4 2022, prices were recorded to drop with values accessed at USD 3252200/MT CFR New York.
APAC
The Asia Pacific Apixaban API market saw high volatility in the fourth quarter of 2022. The Apixaban price rose through the second quarter month due to increased end-user sector demand, several logistical challenges, and rising inflation. The prices at the conclusion of the second month of the fourth quarter were USD 2480020/MT FOB Shanghai. The market remained competitive due to increasing production costs brought on by rising energy prices and increased domestic output to meet demand from domestic and foreign markets. The tight zero covid policies and frequent lockdowns in the Chinese regions have impacted the market. By the end of December, domestic retailers had enough inventories, causing prices to drop to USD 2466500/MT FOB Shanghai. Additionally, other restrictions, including the removal of the zero covid policy, had an impact on the market.
Europe
Market sentiments for Apixaban API in Europe showed erratic volatility in the fourth quarter of 2022. Prices started to rise at the beginning of Q4 2022 and continued to rise through the second month of the quarter as a result of rising end-user sector demand and other logistical difficulties. Zero covid regulations were put into place, which hindered trade and stopped shipments, which benefitted the European Apixaban market. The market remained competitive despite higher manufacturing costs brought on by rising energy prices. Apixaban API prices did drop later in December, though, as domestic dealers had a sufficient supply on hand. The market remained low in December as a result of loosening policy and weak downstream demand. The figures were retrieved at USD 2855200/MT toward the conclusion of Q4.
For the Quarter Ending September 2022
North America
In the third quarter of 2022, market growth was constrained, according to Apixaban price patterns. Due to a decrease in the supply of the API among manufacturers, Apixaban prices increased significantly in the North American market during the first half of Q3. The weak Apixaban market has been sustained by the meager downstream pharmaceutical demand. The US Federal Reserve's tight monetary policy and high-interest rates implemented around the end of the third quarter severely harmed the prospects for domestic commerce. Fears of a recession among traders have made the economic growth barriers stronger. The price of feedstock titanium dioxide among the dealers has also been negatively impacted by the declining price of crude oil. In the final phase of Q3 2022, the value accessed at USD 3250890/MT with an average quarterly declination of 1.43%.
APAC
In the Asia-Pacific region, the market for Apixaban has seen constricted market fundamentals. Apixaban's pricing dynamics have been significantly impacted by declining demand, rising inflation, and large supply, which has kept its market value low in the regional market. On the upstream price front, the declining price of the raw material titanium dioxide has also caused a further decrease in the cost of producing Apixaban. The market feelings around Apixaban, however, were neutralized, and the traders' market value was supported near the end of the quarter by the muted demand from the downstream pharmaceuticals sector. The value accessed at the end of Q3 2022 was USD 2650450/MT, with an average quarterly decline of 3.27%.
Europe
During the third quarter of 2022, price trends of Apixaban gained a downward momentum in the European region. The supply turmoil unleashed by Russia's invasion of Ukraine has severely impacted trade activities across the globe. The upstream input material costs have also been reported on the lower end, prompting declining market sentiments for Apixaban. In addition, the ease in material tariffs and stabilizing fuel and transportation charges have also influenced the operating cost. At the termination of Q3 2022, the value accessed at USD 2924500/MT with an average quarterly declination of 0.65%. Thus, the depreciating costs have been passed on to the terminal consumer at improved prices throughout the third quarter.
For the Quarter Ending June 2022
North America
The price trends of Apixaban have demonstrated mixed market growth during the second quarter of 2022. In the first half of Q2, the price trends of Norfloxacin surged in the North American region, backed by the constrained supply of the API with the manufacturers. The active demand from the downstream pharmaceutical firms has supported the escalated offers of Apixaban. Furthermore, towards the end of the second quarter, the tight monetary policy imposed by US Federal Reserve with high interest has further deteriorated the trade outlook in the domestic region. Recession fears among the traders have further supported the headwinds in economic growth. Also, the dropping crude oil prices have indirectly impacted the price value chain of feedstock Titanium Dioxide among the traders. Altogether, the shrinking energy values and global recession have provoked enough pressure on the market sentiments toward Apixaban at the end of the second quarter. At the termination of Q2 2022 the value accessed at were USD 3395180/MT with the quarterly inclination of 1.7%.
APAC
The Apixaban market has witnessed tight market fundamentals in the Asia-Pacific region. The stringent lockdown restriction in China has declined the production capacities of major manufacturing firms. The curtailed supplies amid severe port congestion have severely impacted the price dynamics of Apixaban and pressured its market value in the domestic region. On the upstream price front, the lowering value of feedstock Titanium Dioxide has also prompted the manufacturing costs of Apixaban to dip further. However, towards the quarter end, the subdued demand from the downstream pharmaceuticals sector has offset Apixaban's market sentiments and supported the traders' market value. At the termination of Q2 2022 the value accessed at were USD 2934830/MT with the quarterly inclination of 3.73%.
Europe
During the second quarter of 2022, price trends of Apixaban gained a downward momentum and significantly showed mixed sentiments in the European region. The supply turmoil unleashed by Russia's invasion of Ukraine has severely impacted trade activities across the globe. On the price front, the upstream input material costs have escalated, prompting enough cost pressure on the market values of Apixaban. As a result, a consistent surge has been observed in manufacturers' quotations. As per the market players, the supply shortages have constrained production capacity as the input costs and output charges have heightened at substantial rates. In addition, the surge in material tariffs and increased fuel and transportation charges have driven up the operating expenses. At the termination of Q2 2022 the value accessed at were USD 2983150/MT with the quarterly declination of 0.20%.Thus, the rising costs have been passed on to the terminal consumer at improved prices throughout the second quarter.
